|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for AZGP1 |
 Gene summary |
| Basic gene Info. | Gene symbol | AZGP1 |
| Gene name | alpha-2-glycoprotein 1, zinc-binding | |
| Synonyms | ZA2G|ZAG | |
| Cytomap | UCSC genome browser: 7q22.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001185.3, | |
| Description | Alpha-2-glycoprotein, zincZn-alpha2-glycoproteinzinc-alpha-2-glycoproteinzn-alpha-2-GPzn-alpha-2-glycoprotein | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 194460 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000160862 | ||
| HPRD : 01910 | ||
| Vega : OTTHUMG00000023066 | ||
| Protein | UniProt: P25311 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_AZGP1 | |
| BioGPS: 563 | ||
| Pathway | NCI Pathway Interaction Database: AZGP1 | |
| KEGG: AZGP1 | ||
| REACTOME: AZGP1 | ||
| Pathway Commons: AZGP1 | ||
| Context | iHOP: AZGP1 | |
| ligand binding site mutation search in PubMed: AZGP1 | ||
| UCL Cancer Institute: AZGP1 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0001580 | detection of chemical stimulus involved in sensory perception of bitter taste | 24248522 | GO:0007155 | cell adhesion | 9813179 |
| Top |
| Ligand binding site mutations for AZGP1 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A178 | A178V | BRCA | 1 | W135 | A133P | COAD | 1 | Y181 | E183G | COAD | 1 | F97 | E99K | SKCM | 1 | F121 | R120M | SKCM | 1 | I96 | D95N | SKCM | 1 | I96 | I96M | THCA | 1 | F97 | E99D | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for AZGP1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | I96 | D95N | -1.1093814 | F121 | R120M | -0.92899669 | W135 | A133P | -0.8768875 | I96 | I96M | -0.85068126 | Y181 | E183G | -0.63371043 | A178 | A178V | -0.53889189 | F97 | E99D | -0.11543002 | F97 | E99K | -0.033497007 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for AZGP1 from PDB |
| Top |
| Differential gene expression and gene-gene network for AZGP1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for AZGP1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0001418 | Adenocarcinoma | 2 | AlteredExpression, Biomarker |
| umls:C0033578 | Prostatic Neoplasms | 2 | AlteredExpression, Biomarker |
| umls:C0024121 | Lung Neoplasms | 1 | Biomarker |
| umls:C0032460 | Polycystic Ovary Syndrome | 1 | Biomarker |
| umls:C0037199 | Sinusitis | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for AZGP1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB03721 | O-Sialic Acid | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of AZGP1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of AZGP1 |
| Multiple alignments for P25311 in multiple species |
| LBS | AA sequence | # species | Species | A178 | VYVQRAKAYLE | 3 | Homo sapiens, Mus musculus, Bos taurus | F121 | VLQGRFGCEIE | 1 | Homo sapiens | F121 | TFQGMFGCEIT | 1 | Mus musculus | F121 | TFQGAFGCELR | 1 | Bos taurus | F97 | AREDIFMETLK | 1 | Homo sapiens | F97 | AREEIFLVTLK | 1 | Mus musculus | F97 | AREDIFMETLS | 1 | Bos taurus | G258 | DVLHNGNGTYQ | 1 | Homo sapiens | G258 | GVFPNGNGTYL | 1 | Mus musculus | G258 | DVLPSGNGTYQ | 1 | Bos taurus | H256 | RGDVLHNGNGT | 1 | Homo sapiens | H256 | ERGVFPNGNGT | 1 | Mus musculus | H256 | GGDVLPSGNGT | 1 | Bos taurus | I96 | KAREDIFMETL | 1 | Homo sapiens | I96 | RAREEIFLVTL | 1 | Mus musculus | I96 | RAREDIFMETL | 1 | Bos taurus | K224 | EKKKLKCLAYD | 1 | Homo sapiens | K224 | GNRIFKCLAYG | 1 | Mus musculus | K224 | HKRTLKCLAYD | 1 | Bos taurus | L226 | KKLKCLAYDFY | 1 | Homo sapiens | L226 | RIFKCLAYGFY | 1 | Mus musculus | L226 | RTLKCLAYDFY | 1 | Bos taurus | R177 | PVYVQRAKAYL | 1 | Homo sapiens | R177 | KVYVQRAKAYL | 1 | Mus musculus | R177 | AVYVQRAKAYL | 1 | Bos taurus | R93 | QLQKAREDIFM | 1 | Homo sapiens | R93 | QLQRAREEIFL | 1 | Mus musculus | R93 | ALQRAREDIFM | 1 | Bos taurus | T212 | PSVVVTSHQAP | 1 | Homo sapiens | T212 | PTVTITSRVIP | 1 | Mus musculus | T212 | PSVSVTGHAAP | 1 | Bos taurus | W135 | SSGAFWKYYYD | 1 | Homo sapiens | W135 | SSGAVWRYAYD | 1 | Mus musculus | W135 | SSGAFWGYAYD | 1 | Bos taurus | W168 | ITKQKWEAEPV | 1 | Homo sapiens | W168 | NTKLKWEAEKV | 1 | Mus musculus | W168 | NTKRKWEAEAV | 1 | Bos taurus | Y137 | GAFWKYYYDGK | 1 | Homo sapiens | Y137 | GAVWRYAYDGE | 1 | Mus musculus | Y137 | GAFWGYAYDGQ | 1 | Bos taurus | Y181 | QRAKAYLEEEC | 3 | Homo sapiens, Mus musculus, Bos taurus | Y34 | SLTYIYTGLSK | 1 | Homo sapiens | Y34 | YLTFLYTGLSR | 1 | Mus musculus | Y34 | SLSFLYTGLSK | 1 | Bos taurus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |